MediSieve named Best Start-up Medtech Company finalist in OBN Awards

 
MediSieve, the company behind the groundbreaking magnetic sieve that removes malaria-infected blood cells, is a finalist in the Best Start-up Medtech Company Award in The OBN Awards 2016.

Now in their eighth year, the OBN (Oxford Biotech Network) Awards cover biotech, medtech, synthetic biology and digital health. Proudly independent, they celebrate innovation and achievement across the UK life sciences industry and recognise achievements from emerging to late stage R&D companies and life sciences investors.

The Best Start-up Medtech Company Award will go to a company less than two years old and which has raised seed or grant funding for product development.

MediSieve was founded in 2015. During the last 12 months, the company has:

•           secured £350,000 in seed funding from angel investors with expertise in the medical device and healthcare industries – they include leading patent attorneys, former CEOs and successful entrepreneurs in the field
•          received a Pathfinder Award from the Wellcome Trust – this provided MediSieve with £102,000 to fund a 12-month project to manufacture and test clinical prototypes of its device

•           won an Innovate UK Smart 2015/16 Proof of Concept Award grant worth £100,000 
  
  
•           taken the runner-up spot at Pitch@Palace 5.0. Held at St. James’s Palace, London, the event saw UK entrepreneurs pitch to around 300 CEOs, angel investors, mentors and key business partners
  
  
•           presented at the Royal Society of Medicine's 12th Medical Innovations Summit
  
  
•           been featured in The Telegraph and many other major journals and publications

Speaking about the nomination for the Best Start-up Medtech Company Award in this year’s OBN Awards, Dr George Frodsham, founder of MediSieve, said: “This is another major high point in what has been amazing year for our business. The recognition and funding that MediSieve has attracted confirms that our magnetic blood filtration technology could play a big part in the global fight against malaria.”

John Harris, CEO of OBN, commented: "We are delighted with the great number of quality entries we received this year, in particular the Best Start-Up Biotech, Best Start-Up Medtech and the Best Implementation of Digital Healthcare Award categories. We are looking forward to celebrating some exciting new businesses and sharing some impressive achievements across the industry at our Awards in October."

A panel of industry experts will decide the overall winner in each category. The winning companies will be announced at the OBN Awards Ceremony on Thursday 6 October at Oxford Town Hall.

JA Kemp, a leading UK and European Patent and Trade Mark Attorney firm that combines independent thinking with collective excellence, sponsors the Best Start-up Medtech Award. Other finalists include:

·                Kindly Oxford Endovascular, which is developing sophisticated mesh tubes to treat patients suffering from brain aneurysm

·                Precision Ocular, the London-based company developing novel therapeutics and drug delivery systems to treat diseases of the back of the eye

MediSieve’s treatment could be used when malaria drugs become ineffective or to supplement existing drug treatments. The magnetic device is aimed at the most vulnerable malaria patients - those whose cases are severe or drug-resistant. It could help patients recover faster, keep symptoms at bay and increase their likelihood of survival.
 

For more information, visit www.medisieve.com and follow on Twitter.

Ends